Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritonavir-Enhanced Agenerase Salvage Therapy in HIV
NCT00006591Phase 2Unknown
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amprenavir in human immunodeficiency virus infection (HIV). Primary endpoint: Safety of Ritonavir-Enhanced Agenerase Regimen. Status: unknown.
02
Drugs
amprenavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00006591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006591.